<DOC>
	<DOCNO>NCT00003936</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient recurrent refractory Hodgkin 's disease .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Recurrent Refractory Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient recurrent refractory Hodgkin 's disease treat bryostatin 1 . II . Determine qualitative quantitative toxicity bryostatin 1 patient . III . Determine duration response survival patient . OUTLINE : Patients receive bryostatin 1 continuous IV infusion 72 hour . Courses repeat every 14 day absence disease progression unacceptable toxicity least 4 course . Patients achieve complete response ( CR ) treat 4 additional course beyond CR . PROJECTED ACCRUAL : A total 14-27 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis recurrent refractory Hodgkin 's disease Measurable disease Must fail follow regimen : Mechlorethamine , vincristine , procarbazine , prednisone ( MOPP ) AND Doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) May undergone either bone marrow peripheral blood stem cell transplant Must eligible standard treatment ( high intensity therapy peripheral blood stem cell bone marrow transplant ) high priority protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count ( ANC ) least 1,000/mm3 ( least 500/mm3 extensive bone marrow involvement ) Platelets least 75,000/mm3 ( least 50,000/mm3 extensive bone marrow involvement ) Hepatic : Bilirubin le 1.5 mg/dL ALT AST less 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 8 week since mitomycin nitrosoureas ) recover Endocrine therapy : No concurrent steroids Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>